3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
35
Motor Activity
25
Breast Neoplasms
5
Urinary Bladder Neoplasms
4
Colorectal Neoplasms
4
Neoplasms
3
Fatigue
3
Carcinoma, Renal Cell
3
Ovarian Neoplasms
2
Obesity
2
Kidney Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Smoking
1
Sleep Initiation and Maintenance Disorders
1
Risk Reduction Behavior
1
Prostatectomy
1
Postoperative Complications
1
Peripheral Nervous System Diseases
1
Patient Preference
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Metabolic Syndrome
1
Mesothelioma, Malignant
1
Malnutrition
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Insulin Resistance
1
Hypoxia
1
Interventions
TH 302
2
Ipilimumab
1
Injections
1
Exercise
1
Circulating Tumor DNA
1
AQ4N
1
3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol
1
3-(4-(2-fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hypoxia
×
Exercise
×
Genitourinary
×
Clear all
NCT03365076
2023-01-09
EXIPOX
University Hospital of North Norway
Phase NA
Terminated
1 enrolled